Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial

The Lancet Respiratory Medicine

Volumn 3, Issue 1, 2015, Pages 24-32

  Wilson, Jennifer G ^a   Liu, Kathleen D ^a   Zhuo, Hanjing ^a   Caballero, Lizette ^a   McMillan, Melanie ^a   Fang, Xiaohui ^a   Cosgrove, Katherine ^b   Vojnik, Rosemary ^c   Calfee, Carolyn S ^a   Lee, Jae Woo ^a   Rogers, Angela J ^c   Levitt, Joseph ^c   Wiener Kronish, Jeanine ^d   Bajwa, Ednan K ^b   Leavitt, Andrew ^e   McKenna, David ^f   Thompson, B Taylor ^b   Matthay, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; DEATH; DISEASE SEVERITY; ENDOTRACHEAL TUBE; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY INFARCTION; LUNG EDEMA; LUNG INFILTRATE; LUNG INJURY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN TENSION; PATIENT SAFETY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; POSITIVE END EXPIRATORY PRESSURE; SPLEEN INFARCTION; THORAX RADIOGRAPHY; UNITED STATES; UNIVERSITY HOSPITAL; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; RESPIRATORY DISTRESS SYNDROME, ADULT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

EID: 84920500515     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70291-7     Document Type: Article

References (35)

1. Matthay MA, Ware LB, Zimmerman GA The acute respiratory distress syndrome. J Clin Invest 2012, 122:2731-2740.
2. Silversides JA, Ferguson ND Clinical review: acute respiratory distress syndrome-clinical ventilator management and adjunct therapy. Crit Care 2012, 17:225.
3. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:301-308. Acute Respiratory Distress Syndrome Network.
4. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354:2564-2575.
5. Papazian L, Forel J-M, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010, 363:1107-1116.
6. Hu SL, He HL, Pan C, et al. The effect of prone positioning on mortality in patients with acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Crit Care 2014, 18:R109.
7. Guérin C, Reignier J, Richard J-C, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013, 368:2159-2168.
8. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012, 307:8. The ARDS Definition Task Force.
9. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007, 179:1855-1863.
10. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009, 106:16357-16362.
11. Fang X, Neyrinck AP, Matthay MA, Lee JW Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 2010, 285:26211-26222.
12. Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012, 67:533-539.
13. Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012, 302:L1003-L1013.
14. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010, 28:2229-2238.
15. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013, 187:751-760.
16. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
17. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007, 104:11002-11007.
18. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010, 182:1047-1057.
19. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA Concise review: mesenchymal stem cells for acute lung injury: role of Paracrine Soluble Factors. Stem Cells 2011, 29:913-919.
20. Walter J, Ware LB, Matthay MA Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014, 2:1016-1026.
21. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012, 18:759-765.
22. Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012, 67:496-501.
23. McAuley DF, Curley GF, Hamid UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol 2014, 306:L809-L815.
24. Asmussen S, Ito H, Traber DL, et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014, 69:819-825.
25. Zheng G, Lanfang H, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014, 15:39.
26. Liu KD, Wilson JG, Zhuo H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care 2014, 4:22.
27. Murray JF, Matthay MA, Luce JM, Flick MR An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138:720-723.
28. Kangelaris KN, Calfee CS, May AK, Zhuo H, Matthay MA, Ware LB Is there still a role for the lung injury score in the era of the Berlin definition ARDS?. Ann Intensive Care 2014, 4:4.
29. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
30. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758.
31. Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005, 33:1-6.
32. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 2012, 40:1731.
33. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008, 63:1083-1089.
34. Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014, 164:966-972.
35. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013, 143:1590-1598.